Europe bets on Pfizer vaccine

Avatar of Nick John By Nick John Dec7,2023 #Europe #Pfizer #Vaccine
Europe bets on Pfizer vaccine 6
Europe bets on Pfizer vaccine 6

European Commission President Ursula von der Leyen said the 50 million Pfizer doses initially expected to be distributed in the fourth quarter will be delivered soon, from April to next June.

Ms. Von der Leyen also negotiated further with Pfizer-BioNTech to purchase an additional 1.8 billion doses of vaccine for 2022-2023.

`We need to focus on technologies that have been proven effective. The mRNA vaccine is a clear example,` she said on April 13.

She added that Pfizer is delivering on its commitments and meeting European needs.

The announcement was made by the EU after Johnson & Johnson (J&J) stopped deploying the vaccine in Europe because of concerns about rare cases of blood clotting.

`Based on scientific evidence, our general assessment is that side effects from the AstraZeneca vaccine pose a real risk,` said Soren Brostrom, director of the Danish Health Authority.

Pfizer vaccine was deployed at Rathenow Vaccination Center, Germany, April 14.

Both vaccines are based on vector technology, using harmless cold viruses to introduce nCoV proteins into human cells, helping to stimulate the immune system’s response.

The EU initially bet heavily on the AstraZeneca and J&J vaccines, buying hundreds of millions of doses from both companies.

The entire EU is still giving the AstraZeneca vaccine to the elderly, but some countries have different rules when using it for younger people.

Meanwhile, the European Medicines Agency is investigating blood clotting symptoms in a small number of people receiving the J&J vaccine.

While the purchase of more Pfizer vaccines is welcomed in Europe, it raises questions about the fairness of the global vaccination program.

Pfizer said it can produce more than 3 billion doses of vaccine next year.

`It puts the EU at higher risk in production. What if later this year there is a new generation mRNA vaccine, more effective, easier to provide, stored at higher temperatures, and has a good supply?

The EU’s gamble on mRNA vaccines can also easily cause Pfizer and BioNTech to push up product prices.

Pfizer declined to comment on this information.

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *